Psychedelic and ketamine research trials in Canada
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
79 registered studies are counted in Canada. By compound: 39 psilocybin, 4 MDMA, 1 LSD and 36 ketamine. By registry status: 23 recruiting, 8 not yet recruiting, 1 enrolling by invitation, 9 active, not recruiting, 20 completed, 4 terminated, 2 suspended, 2 withdrawn and 10 status not reported. By phase: 1 early phase 1, 11 phase 1, 42 phase 2, 6 phase 3, 4 phase 4, 8 not applicable and 7 not reported. Reported start years run from 2013 (earliest) to 2026 (latest). Studies are linked to 37 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
31 of the 79 counted studies are listed in the registry as recruiting (23) or not yet recruiting (8), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial | NCT07791901 | Not yet recruiting | Phase 2 | 2026-10-30 | University of Calgary, Calgary |
| Oral and Sublingual Ketamine | NCT07683988 | Not yet recruiting | Phase 1 | 2026-10-01 | Western University, Canada, London |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial | NCT07820033 | Not yet recruiting | Phase 2 | 2026-09-14 | University Health Network, Toronto, Toronto |
| Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression | NCT07801703 | Not yet recruiting | Phase 2 | 2026-09-01 | The Royal's Institute of Mental Health Research, Ottawa |
| Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence | NCT06885996 | Not yet recruiting | Phase 2 | 2026-08-01 | University of Calgary, Calgary |
| Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study | NCT07614581 | Not yet recruiting | Not reported | 2026-07-15 | Dr. Adriaan van der Wart Medical Corp., Ganges |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | NCT07569198 | Recruiting | Phase 2 | 2026-06-01 | University Health Network, Toronto, Toronto |
| InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression | NCT06781697 | Recruiting | Phase 3 | 2026-05-01 | Sunnybrook Health Sciences Centre, Toronto |
| Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy | NCT07373535 | Not yet recruiting | Phase 2 | 2026-05-01 | Sir Mortimer B. Davis - Jewish General Hospital, Montreal |
| Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression | NCT07211438 | Recruiting | Phase 2 | 2026-04-01 | Centre for Addiction and Mental Health, Toronto |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder | NCT07405606 | Not yet recruiting | Phase 2 | 2026-03-01 | Centre for Addiction and Mental Health, Toronto |
| Subjective Experience Following Psilocybin | NCT06768944 | Recruiting | Phase 2 | 2026-02-01 | University of Calgary, Calgary |
| Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT) | NCT07063862 | Recruiting | Phase 3 | 2026-01-01 | Bruyère Health Research Institute., Brampton |
| Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication | NCT05585229 | Recruiting | Phase 2 | 2025-10-27 | University of British Columbia, Kelowna |
| Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder | NCT06943573 | Recruiting | Phase 3 | 2025-10-01 | University of British Columbia, Vancouver |
| Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD | NCT07009158 | Recruiting | Phase 1 | 2025-10-01 | Queen's University, Kingston |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer | NCT07048743 | Recruiting | Phase 2 | 2025-07-02 | University Health Network, Toronto, Toronto |
| Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy | NCT06615908 | Recruiting | Phase 1 | 2025-05-27 | University of Calgary, Calgary |
| Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder | NCT06969170 | Recruiting | Phase 2 | 2025-05-06 | Queen's University, Kingston |
| ACT_for Alcohol Use Disorder and Depression | NCT06620276 | Recruiting | Not applicable | 2025-05-01 | Centre hospitalier de l'Université de Montréal (CHUM), Montreal |
| Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) | NCT06512220 | Recruiting | Phase 2 | 2025-04-21 | Centre for Addiction and Mental Health, Toronto |
| Understanding and Treating Suicidal Ideation With Ketamine | NCT06891300 | Recruiting | Phase 2 | 2025-04-08 | The Royal's Institute of Mental Health Research, Ottawa |
| Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | NCT06518720 | Recruiting | Phase 2 | 2025-04-01 | Centre for Addiction and Mental Health, Toronto |
| A Randomized Neuroimaging Trial of Psilocybin in Depression | NCT06072898 | Recruiting | Phase 2 | 2025-03-25 | Sunnybrook Health Sciences Centre, Toronto |
| Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN | NCT06731335 | Recruiting | Phase 2 | 2025-03-05 | Unity Health Toronto, Toronto |
| Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer | NCT06818994 | Recruiting | Phase 1 | 2025-03-01 | Queen's University, Kingston |
| MDMA-Assisted CBCT for PTSD vs CBCT RCT | NCT06044675 | Recruiting | Phase 2 | 2024-11-15 | Remedy, Toronto |
| Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder | NCT05995769 | Recruiting | Phase 2 | 2024-03-20 | University of Calgary, Calgary |
| IV Ketamine Vs. in Esketamine for MDD TRD | NCT06488586 | Recruiting | Not reported | 2023-03-20 | Queen's University, Kingston |
| Ketamine Enhances Analgesia and Mood in Chronic Pain Patients | NCT05985811 | Recruiting | Not reported | 2018-02-02 | Salem Anaesthesia Pain Clinic, Surrey |
| ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression | NCT03272698 | Recruiting | Phase 4 | 2017-09-01 | University of Saskatchewan, Saskatoon |
At a glance
- 79 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 39 |
| MDMA | 4 |
| LSD | 1 |
| Ketamine | 36 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 23 | 29% |
| Not yet recruiting | 8 | 10% |
| Enrolling by invitation | 1 | 1% |
| Active, not recruiting | 9 | 11% |
| Completed | 20 | 25% |
| Terminated | 4 | 5% |
| Suspended | 2 | 3% |
| Withdrawn | 2 | 3% |
| Status not reported | 10 | 13% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 1% |
| Phase 1 | 11 | 14% |
| Phase 2 | 42 | 53% |
| Phase 3 | 6 | 8% |
| Phase 4 | 4 | 5% |
| Not applicable | 8 | 10% |
| Not reported | 7 | 9% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 43 |
| 2020 to 2023 | 24 |
| 2015 to 2019 | 10 |
| 2010 to 2014 | 2 |
All counted studies
All 79 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial | NCT07791901 | Not yet recruiting | Phase 2 | 2026-10-30 | University of Calgary, Calgary |
| Oral and Sublingual Ketamine | NCT07683988 | Not yet recruiting | Phase 1 | 2026-10-01 | Western University, Canada, London |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial | NCT07820033 | Not yet recruiting | Phase 2 | 2026-09-14 | University Health Network, Toronto, Toronto |
| Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression | NCT07801703 | Not yet recruiting | Phase 2 | 2026-09-01 | The Royal's Institute of Mental Health Research, Ottawa |
| Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence | NCT06885996 | Not yet recruiting | Phase 2 | 2026-08-01 | University of Calgary, Calgary |
| Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study | NCT07614581 | Not yet recruiting | Not reported | 2026-07-15 | Dr. Adriaan van der Wart Medical Corp., Ganges |
| Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression | NCT07737990 | Enrolling by invitation | Not applicable | 2026-07-01 | University Health Network, Toronto, Toronto |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | NCT07569198 | Recruiting | Phase 2 | 2026-06-01 | University Health Network, Toronto, Toronto |
| InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression | NCT06781697 | Recruiting | Phase 3 | 2026-05-01 | Sunnybrook Health Sciences Centre, Toronto |
| Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy | NCT07373535 | Not yet recruiting | Phase 2 | 2026-05-01 | Sir Mortimer B. Davis - Jewish General Hospital, Montreal |
| Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression | NCT07211438 | Recruiting | Phase 2 | 2026-04-01 | Centre for Addiction and Mental Health, Toronto |
| Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD | NCT06386003 | Active, not recruiting | Phase 2 | 2026-03-01 | Unity Health Toronto, Toronto |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder | NCT07405606 | Not yet recruiting | Phase 2 | 2026-03-01 | Centre for Addiction and Mental Health, Toronto |
| Subjective Experience Following Psilocybin | NCT06768944 | Recruiting | Phase 2 | 2026-02-01 | University of Calgary, Calgary |
| Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT) | NCT07063862 | Recruiting | Phase 3 | 2026-01-01 | Bruyère Health Research Institute., Brampton |
| Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication | NCT05585229 | Recruiting | Phase 2 | 2025-10-27 | University of British Columbia, Kelowna |
| Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder | NCT06943573 | Recruiting | Phase 3 | 2025-10-01 | University of British Columbia, Vancouver |
| Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD | NCT07009158 | Recruiting | Phase 1 | 2025-10-01 | Queen's University, Kingston |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer | NCT07048743 | Recruiting | Phase 2 | 2025-07-02 | University Health Network, Toronto, Toronto |
| Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy | NCT06615908 | Recruiting | Phase 1 | 2025-05-27 | University of Calgary, Calgary |
| Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder | NCT06969170 | Recruiting | Phase 2 | 2025-05-06 | Queen's University, Kingston |
| ACT_for Alcohol Use Disorder and Depression | NCT06620276 | Recruiting | Not applicable | 2025-05-01 | Centre hospitalier de l'Université de Montréal (CHUM), Montreal |
| Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) | NCT06512220 | Recruiting | Phase 2 | 2025-04-21 | Centre for Addiction and Mental Health, Toronto |
| Understanding and Treating Suicidal Ideation With Ketamine | NCT06891300 | Recruiting | Phase 2 | 2025-04-08 | The Royal's Institute of Mental Health Research, Ottawa |
| Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | NCT06518720 | Recruiting | Phase 2 | 2025-04-01 | Centre for Addiction and Mental Health, Toronto |
| A Randomized Neuroimaging Trial of Psilocybin in Depression | NCT06072898 | Recruiting | Phase 2 | 2025-03-25 | Sunnybrook Health Sciences Centre, Toronto |
| Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN | NCT06731335 | Recruiting | Phase 2 | 2025-03-05 | Unity Health Toronto, Toronto |
| Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study | NCT06225232 | Active, not recruiting | Phase 2 | 2025-03-01 | McMaster University, Hamilton |
| Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer | NCT06818994 | Recruiting | Phase 1 | 2025-03-01 | Queen's University, Kingston |
| Psychedelic-assisted Group Program for First Responders | NCT06471959 | Status not reported | Phase 1 | 2025-01-01 | Empower Research Inc, Surrey |
| MDMA-Assisted CBCT for PTSD vs CBCT RCT | NCT06044675 | Recruiting | Phase 2 | 2024-11-15 | Remedy, Toronto |
| The Effects of Psilocybin on Shared Experience in Film Processing | NCT06529939 | Status not reported | Not applicable | 2024-11-01 | Western University, Canada, London |
| Psilocybin for Treatment-Resistant Depression in Autism | NCT06731621 | Active, not recruiting | Phase 1 | 2024-11-01 | Centre for Addiction and Mental Health, Toronto |
| Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression | NCT06506019 | Active, not recruiting | Phase 1 | 2024-10-09 | University Health Network, Toronto, Toronto |
| Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD | NCT06299319 | Completed | Phase 1 | 2024-09-01 | Centre for Addiction and Mental Health, Toronto |
| Behavioural Activation Therapy and Esketamine for Resistant Depression | NCT06431386 | Terminated | Not applicable | 2024-06-11 | The Royal's Institute of Mental Health Research, Ottawa |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | NCT06416085 | Active, not recruiting | Phase 2 | 2024-06-06 | University Health Network, Toronto, Toronto |
| Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder | NCT05995769 | Recruiting | Phase 2 | 2024-03-20 | University of Calgary, Calgary |
| Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin | NCT06341426 | Active, not recruiting | Phase 2 | 2024-02-05 | University Health Network, Toronto, Toronto |
| Predictors of Intravenous Ketamine Response in TRD | NCT05625555 | Active, not recruiting | Phase 3 | 2024-01-19 | Nova Scotia Health Authority, Halifax |
| Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation | NCT06366334 | Status not reported | Not applicable | 2024-01-15 | Children's Hospital of Eastern Ontario, Ottawa |
| PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL) | NCT04754061 | Active, not recruiting | Phase 1 | 2024-01-08 | Ottawa Hospital Research Institute, Ottawa |
| i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial | NCT06480500 | Active, not recruiting | Phase 2 | 2024-01-02 | University Health Network, Toronto, Toronto |
| Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment | NCT06041152 | Completed | Phase 2 | 2023-11-27 | Centre for Addiction and Mental Health, Toronto |
| Microdosing Psychedelics to Improve Mood | NCT05259943 | Completed | Phase 2 | 2023-07-15 | University of Toronto, Toronto |
| Does Psilocybin Require Psychedelic Effects to Treat Depression? | NCT05710237 | Completed | Phase 2 | 2023-07-01 | Centre for Addiction and Mental Health, Toronto |
| Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation | NCT05468840 | Status not reported | Phase 3 | 2023-06-01 | University of Ottawa, Ottawa |
| An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome | NCT05832255 | Suspended | Phase 2 | 2023-03-28 | Nova Mentis Life Science Corp, London |
| IV Ketamine Vs. in Esketamine for MDD TRD | NCT06488586 | Recruiting | Not reported | 2023-03-20 | Queen's University, Kingston |
| Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study | NCT05438758 | Withdrawn | Phase 2 | 2023-01-15 | Zylorion Health, Edmonton |
| Effect of SSRIs on Response to Psilocybin Therapy | NCT05594667 | Withdrawn | Phase 2 | 2023-01-01 | Cybin Therapeutics Inc., Abbotsford |
| Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression | NCT05323019 | Terminated | Phase 2 | 2022-10-13 | Zylorion Health, Edmonton |
| Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder | NCT05243329 | Status not reported | Phase 2 | 2022-10-03 | Halucenex Life Sciences Inc., Windsor |
| Auditory MMN EEG in TRD in Response to Ketamine | NCT05464264 | Status not reported | Not reported | 2022-10-03 | Unity Health Toronto, Toronto |
| Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression | NCT05339074 | Completed | Phase 2 | 2022-08-11 | University Health Network, Toronto, Toronto |
| Ketamine for Treatment-Resistant Bipolar Disorder | NCT05004896 | Completed | Phase 2 | 2022-07-04 | University Health Network, Toronto, Toronto |
| Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics | NCT04955470 | Terminated | Phase 1 | 2022-06-01 | University of British Columbia, Vancouver |
| Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression | NCT05177146 | Completed | Not applicable | 2022-05-04 | Centre for Addiction and Mental Health, Toronto |
| Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD) | NCT05646303 | Status not reported | Phase 2 | 2022-05-02 | Clairvoyant Therapeutics, Calgary |
| Chart Review of Patients Undergoing Ketamine Treatments for Depression | NCT07099235 | Completed | Not reported | 2022-04-01 | Sunnybrook Health Sciences Centre, Mississauga |
| Psilocybin for Treatment-Resistant Depression | NCT05029466 | Completed | Phase 2 | 2021-11-19 | Brain and Cognition Discovery Foundation, Mississauga |
| Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders) | NCT05137938 | Completed | Not applicable | 2021-10-25 | Centre for Addiction and Mental Health, Toronto |
| Identification of a Safe and Non-Psychedelic Dose of Psilocybin | NCT07710027 | Completed | Phase 1 | 2021-10-19 | Diamond Therapeutics Inc., Toronto |
| A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD) | NCT05067244 | Completed | Phase 2 | 2021-10-04 | Remedy, Toronto |
| Combined Ketamine and eCBT Intervention for PTSD | NCT04771767 | Status not reported | Phase 2 | 2021-08-01 | Queen's University, Kingston |
| Pharmacogenetics Associated With IV Ketamine | NCT04695405 | Completed | Not reported | 2021-01-21 | Brain and Cognition Discovery Foundation, Mississauga |
| Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression | NCT04701866 | Completed | Not applicable | 2021-01-11 | Douglas Mental Health University Institute, Montreal |
| Chart Review of Patients Undergoing Ketamine Infusions | NCT04209296 | Completed | Not reported | 2019-12-03 | Brain and Cognition Discovery Foundation, Mississauga |
| Ketamine Co-induction for Patients With Major Depressive Disorder | NCT03666494 | Status not reported | Phase 4 | 2018-12-01 | University of Saskatchewan, Saskatoon |
| Ketamine Versus Electroconvulsive Therapy in Depression | NCT03674671 | Suspended | Phase 3 | 2018-10-29 | University of Ottawa, Kingston |
| Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care | NCT03410446 | Completed | Phase 2 | 2018-07-16 | University Health Network, Toronto, Toronto |
| Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada) | NCT03485287 | Completed | Phase 2 | 2018-03-13 | Lykos Therapeutics, Vancouver |
| Ketamine Enhances Analgesia and Mood in Chronic Pain Patients | NCT05985811 | Recruiting | Not reported | 2018-02-02 | Salem Anaesthesia Pain Clinic, Surrey |
| ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression | NCT03272698 | Recruiting | Phase 4 | 2017-09-01 | University of Saskatchewan, Saskatoon |
| Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression | NCT02924090 | Status not reported | Phase 4 | 2016-09-01 | University of Manitoba, Winnipeg |
| Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. | NCT02593643 | Completed | Early Phase 1 | 2016-01-01 | Sunnybrook Health Sciences Centre, Toronto |
| Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy | NCT02579642 | Completed | Phase 4 | 2015-10-01 | University of Alberta, Edmonton |
| Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD | NCT01958593 | Terminated | Phase 2 | 2014-10-14 | Lykos Therapeutics, Vancouver |
| Action of Ketamine in Treatment-Resistant Depression | NCT01945047 | Completed | Phase 2 | 2013-05-01 | University of Ottawa, Ottawa |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | Ketamine
Institution hubs in this country
Institutions in this country with at least 3 counted studies. The number is that institution's own count of studies, which can include studies not shown above if the registry lists them under another country.
- University Health Network, Toronto: 11 studies
- Centre for Addiction and Mental Health: 10 studies
- Queen's University: 5 studies
- University of Calgary: 5 studies
- Brain and Cognition Discovery Foundation: 3 studies
- Sunnybrook Health Sciences Centre: 3 studies
- The Royal's Institute of Mental Health Research: 3 studies
- Unity Health Toronto: 3 studies
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
Other country hubs
United States | Switzerland | United Kingdom | France | Israel | Brazil | China | Netherlands | Australia | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland